Table 2. Multivariate logistic regression model of pathologic complete response (345 out of 793 patients; 43.5%).
| Covariate | OR | 95% CI | P |
|---|---|---|---|
| ER expression | 0.99 | 0.98–0.99 | <0.001 |
| PR expression | 1 | 0.99–1.00 | 0.21 |
| HER2/CEP17 ratio | 1.05 | 1.004–1.10 | 0.03 |
| IBC or non-IBC | |||
| IBC | 1 | ||
| Non-IBC | 2.23 | 1.30–3.82 | 0.003 |
| Neoadjuvant systemic therapy regimen | |||
| Cytotoxic agents alone | 1 | ||
| TmAb | 3.41 | 2.08–5.61 | <0.001 |
| TmAb and PmAb | 4.03 | 2.05–7.91 | <0.001 |
Abbreviations: CI=confidence interval; ER=oestrogen receptor; HER2=human epidermal growth factor receptor 2; IBC=inflammatory breast cancer; OR=odds ratio; PmAb=pertuzumab; PR=progesterone receptor; TmAb=trastuzumab.